TCON TRACON Pharmaceuticals Inc.

2.20
-0.03  -1%
Previous Close 2.23
Open 2.25
Price To book 1.79
Market Cap 38940000
Shares 17,700,000
Volume 377,752
Short Ratio 0.92
Av. Daily Volume 186,602

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced December 1, 2017.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1b enrollment to be completed 2018.
TRC105 + Avastin
Non-Squamous Cell Lung Cancer
Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due 1H 2018.
TRC253
Prostate cancer
Phase 2 AVANTE trial initiation announced July 25, 2017.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with poster presented January 19, 2018 at ASCO GI showing 2/8 partial responses.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line PFS data due 1H 2018.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 2018.
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2018.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis 2H 2018.
TRC105 (TAPPAS)
Angiosarcoma cancer